For research use only. Not for therapeutic Use.
Novel DNA alkylating agent exhibiting superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo (IC50 values 5-50 µM for cytotoxicity on glioma cell lines). NEO 212 causes DNA damage and cell death much more efficiently than TMZ, because linkage with POH increased its biological half-life and thus provided greater opportunity for placement of cytotoxic DNA lesions.NEO212 is a conjugate of temozolomide (TMZ, Axon 2326) with the natural product perillyl alcohol (POH) and circumvents TMZ-resistance in multiple cancer cell lines and gliomas.
| Catalog Number | I047607 |
| CAS Number | 1361198-79-9 |
| Molecular Formula | C17H20N6O4 |
| Purity | ≥95% |
| IUPAC Name | [(4S)-4-prop-1-en-2-ylcyclohexen-1-yl]methyl N-(3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carbonyl)carbamate |
| InChI | InChI=1S/C17H20N6O4/c1-10(2)12-6-4-11(5-7-12)8-27-16(25)19-15(24)13-14-20-21-22(3)17(26)23(14)9-18-13/h4,9,12H,1,5-8H2,2-3H3,(H,19,24,25)/t12-/m1/s1 |
| SMILES | CC(=C)[C@H]1CCC(=CC1)COC(=O)NC(=O)C2=C3N=NN(C(=O)N3C=N2)C |
| Reference | T.C. Chen et al. A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo. Mol. Cancer Ther. 2014, 13, 1181-1193.
H.Y. Cho et al. NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas. Mol. Cancer Ther. 2014, 13, 2004-2017. |
